ArticleMolecular & cellular proteomics : MCP2015
Proteomics of microparticles with SILAC Quantification (PROMIS-Quan): a novel proteomic method for plasma biomarker quantification.
Article in Molecular & cellular proteomics : MCP, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Distinct protein profiles in cord blood plasma of children with autism spectrum disorder.Scientific reports · 2025Article
- Molecular insights into the unique properties of the blood-circulating proteasome.Journal of extracellular biology · 2025Article
- Neat plasma proteomics: getting the best out of the worst.Clinical proteomics · 2024Article
- Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.Cancer immunology, immunotherapy : CII · 2024Article
- Article
- Deep proteomic analysis of obstetric antiphospholipid syndrome by DIA-MS of extracellular vesicle enriched fractions.Communications biology · 2024Article
- Proteomics of Plasma and Plasma-Treated Podocytes: Application to Focal and Segmental Glomerulosclerosis.International journal of molecular sciences · 2023Article
- Biology of the Extracellular Proteasome.Biomolecules · 2022Review
- Microparticles: biogenesis, characteristics and intervention therapy for cancers in preclinical and clinical research.Journal of nanobiotechnology · 2022Review
- Purification and Phosphoproteomic Analysis of Plasma-Derived Extracellular Vesicles.Methods in molecular biology (Clifton, N.J.) · 2022Article
- HBFP: a new repository for human body fluid proteome.Database : the journal of biological databases and curation · 2021Article
- Human body-fluid proteome: quantitative profiling and computational prediction.Briefings in bioinformatics · 2021Review
- Multi-Omics Data Integration in Extracellular Vesicle Biology-Utopia or Future Reality?International journal of molecular sciences · 2020Review
- Breast Cancer-Derived Microparticles Reduce Cancer Cell Adhesion, an Effect Augmented by Chemotherapy.Cells · 2020Article
- Selectively-Packaged Proteins in Breast Cancer Extracellular Vesicles Involved in Metastasis.International journal of molecular sciences · 2020Article
- Plasma-Derived Extracellular Vesicle Phosphoproteomics through Chemical Affinity Purification.Journal of proteome research · 2020Article
- An Update on Isolation Methods for Proteomic Studies of Extracellular Vesicles in Biofluids.Molecules (Basel, Switzerland) · 2019Review
- Harnessing the tissue and plasma lncRNA-peptidome to discover peptide-based cancer biomarkers.Scientific reports · 2019Article
- Microvesicle Proteomic Profiling of Uterine Liquid Biopsy for Ovarian Cancer Early Detection.Molecular & cellular proteomics : MCP · 2019Article
- Highly Efficient Phosphoproteome Capture and Analysis from Urinary Extracellular Vesicles.Journal of proteome research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unbiased proteomic analysis of plasma samples holds the promise to reveal clinically invaluable disease biomarkers. However, the tremendous dynamic range of the plasma proteome has so far hampered the identification of such low abundant markers. To overcome this challenge we analyzed the plasma microparticle proteome, and reached an unprecedented depth of over 3000 plasma proteins in single runs. To add a quantitative dimension, we developed PROMIS-Quan-PROteomics of MIcroparticles with Super-Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantification, a novel mass spectrometry-based technology for plasma microparticle proteome quantification. PROMIS-Quan enables a two-step relative and absolute SILAC quantification. First, plasma microparticle proteomes are quantified relative to a super-SILAC mix composed of cell lines from distinct origins. Next, the absolute amounts of selected proteins of interest are quantified relative to the super-SILAC mix. We applied PROMIS-Quan to prostate cancer and compared plasma microparticle samples of healthy individuals and prostate cancer patients. We identified in total 5374 plasma-microparticle proteins, and revealed a predictive signature of three proteins that were elevated in the patient-derived plasma microparticles. Finally, PROMIS-Quan enabled determination of the absolute quantitative changes in prostate specific antigen (PSA) upon treatment. We propose PROMIS-Quan as an innovative platform for biomarker discovery, validation, and quantification in both the biomedical research and in the clinical worlds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.